Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from AbbVie, Celgene, Genentech, and Gilead.
Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia
Jeffrey Jones, MD/MPH
Ohio State University Comprehensive Cancer Center
Mollie Moran, CNP
The James Cancer Hospital at The Ohio State University
Oncology care is undergoing dynamic changes across tumor types with novel therapies being developed at a rapid pace. Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, the need for advanced practitioners (APs) to stay up to date and informed in order to translate these advances into the clinical setting is daunting. This educational activity will provide APs with important information on the diagnostic workup, risk assessment/prognostic indicators, optimizing treatment selection, response monitoring, mechanism of actions, and side effect management of newer therapies.
These CME/CE/CPE accredited activities are jointly provided by
